Insmed has been granted a patent for a method to treat lupus nephritis using compounds that inhibit dipeptidyl peptidase 1 activity. The method involves administering a pharmaceutical composition containing a specific compound, INS1007. GlobalData’s report on Insmed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Insmed, Peptide pharmacophores was a key innovation area identified from patents. Insmed's grant share as of May 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of lupus nephritis with ins1007 compound
A recently granted patent (Publication Number: US11998553B2) discloses a method for treating lupus nephritis (LN) in patients by administering a pharmaceutical composition containing a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) includes various specific chemical structures, such as (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide, among others. The method involves oral administration of the composition and aims to decrease serum creatinine levels, active urinary sediment, proteinuria, and achieve a complete or partial renal response in patients suffering from LN.
Furthermore, the method may include the administration of additional active agents like corticosteroids or immunosuppressants, such as mycophenolate mofetil (MFF) or azathioprine, to enhance the treatment efficacy. The treatment process also involves monitoring various parameters like urinary protein to creatinine ratio (UPCR), urine albumin to creatinine ratio (UACR), and achieving an inactive urinary sediment with specific criteria. The patent outlines a comprehensive approach to managing LN by combining the compound of formula (I) with other active agents to improve patient outcomes and potentially achieve complete remission of the disease.
To know more about GlobalData’s detailed insights on Insmed, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
